目的 探讨脑脉泰胶囊联合奥拉西坦注射液治疗血管性痴呆的临床疗效。方法 选取2014年9月-2016年9月商丘市第五人民医院神经内科收治的血管性痴呆患者108例，所有患者在随机分组的原则下分成对照组和治疗组，每组各54例。对照组静脉滴注奥拉西坦注射液，4.0 g加入到5%葡萄糖溶液250 mL中，1次/d。治疗组在对照组基础上口服脑脉泰胶囊，2粒/次，3次/d。两组均治疗1个月。观察两组的临床疗效，比较两组炎症因子、认知功能和日常生活质量。结果 治疗后，对照组和治疗组的总有效率分别为68.52%、90.74%，两组比较差异有统计学意义（P<0.05）。治疗后，两组血清肿瘤坏死因子（TNF-α）、白细胞介素-6（IL-6）和C-反应蛋白（CRP）水平均显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的下降程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组MMSE评分和ADL评分均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的升高程度明显优于对照组，两组比较差异有统计学意义（P<0.05）。结论 脑脉泰胶囊联合奥拉西坦注射液治疗血管性痴呆具有较好的临床疗效，可改善认知功能和日常生活质量，降低炎症因子水平，具有一定临床推广应用价值。

Objective To explore the clinical effect of Naomaitai Capsules combined with Oxiracetam Injection in treatment of vascular dementia. Methods Patients (104 cases) with vascular dementia in Department of Neurology of Shangqiu Fifth People's Hospital from September 2014 to September 2016 were randomly divided into control and treatment groups, and each group had 54 cases. Patients in the control group were iv administered with Oxiracetam Injection, 4.0 g added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were po administered with Naomaitai Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and inflammatory indexes, cognitive function, and quality of life in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 68.52% and 90.74%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of TNF-α, IL-6, and CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, MMSE scores and ADL scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Naomaitai Capsules combined with Oxiracetam Injection has clinical curative effect in treatment of vascular dementia, and can improve cognitive function and quality of life and decrease the levels of inflammatory indexes, which has a certain clinical application value.